Advaxis, Inc. (ADXS)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.43 Million USD | 113.63% |
| 2022 | -25.19 Million USD | 39.39% |
| 2021 | -41.57 Million USD | -116.97% |
| 2020 | -19.16 Million USD | -16.65% |
| 2019 | -16.42 Million USD | 62.79% |
| 2018 | -44.14 Million USD | -84.69% |
| 2017 | -23.89 Million USD | -111.25% |
| 2016 | 212.4 Million USD | 419.26% |
| 2015 | -66.53 Million USD | -279.23% |
| 2014 | -17.54 Million USD | 13.69% |
| 2013 | -20.32 Million USD | -4360.85% |
| 2012 | 477.04 Thousand USD | 505.42% |
| 2011 | -117.66 Thousand USD | -108.85% |
| 2010 | 1.33 Million USD | -47.64% |
| 2009 | 2.54 Million USD | 399.64% |
| 2008 | 508.39 Thousand USD | 112.9% |
| 2007 | -3.94 Million USD | -242.77% |
| 2006 | 2.76 Million USD | 275.35% |
| 2005 | -1.57 Million USD | -259.67% |
| 2004 | 986.14 Thousand USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | 1.35 Million USD | 124.51% |
| 2023 Q2 | -5.53 Million USD | 63.51% |
| 2023 Q1 | -15.17 Million USD | -2209.89% |
| 2023 FY | 3.43 Million USD | 113.63% |
| 2023 Q4 | 3.43 Million USD | 153.06% |
| 2022 Q3 | -25.19 Million USD | 10.43% |
| 2022 FY | -25.19 Million USD | 39.39% |
| 2022 Q4 | -657 Thousand USD | 97.39% |
| 2022 Q1 | -32.05 Million USD | 12.04% |
| 2022 Q2 | -28.13 Million USD | 12.25% |
| 2021 Q4 | -36.44 Million USD | 12.33% |
| 2021 Q3 | -41.57 Million USD | 5.32% |
| 2021 Q2 | -43.91 Million USD | 20.92% |
| 2021 FY | -41.57 Million USD | -116.97% |
| 2021 Q1 | -55.52 Million USD | -33.89% |
| 2020 Q2 | -56.82 Million USD | -497.68% |
| 2020 Q4 | -41.47 Million USD | -116.44% |
| 2020 FY | -19.16 Million USD | -16.65% |
| 2020 Q1 | -9.5 Million USD | 42.12% |
| 2020 Q3 | -19.16 Million USD | 66.28% |
| 2019 FY | -16.42 Million USD | 62.79% |
| 2019 Q4 | -16.42 Million USD | 49.24% |
| 2019 Q3 | -32.36 Million USD | 22.49% |
| 2019 Q2 | -41.75 Million USD | -23.88% |
| 2019 Q1 | -33.7 Million USD | -3.04% |
| 2018 Q2 | -39.43 Million USD | 19.32% |
| 2018 FY | -44.14 Million USD | -84.69% |
| 2018 Q1 | -48.87 Million USD | -88.48% |
| 2018 Q3 | -44.14 Million USD | -11.94% |
| 2018 Q4 | -32.71 Million USD | 25.9% |
| 2017 Q2 | -14.71 Million USD | 50.47% |
| 2017 Q1 | -29.71 Million USD | 48.09% |
| 2017 FY | -23.89 Million USD | -111.25% |
| 2017 Q4 | -25.93 Million USD | -8.5% |
| 2017 Q3 | -23.89 Million USD | -62.38% |
| 2016 Q1 | -44.92 Million USD | 23.39% |
| 2016 Q2 | -29.4 Million USD | 34.54% |
| 2016 Q4 | -57.25 Million USD | -126.95% |
| 2016 Q3 | 212.4 Million USD | 822.31% |
| 2016 FY | 212.4 Million USD | 419.26% |
| 2015 Q3 | -66.53 Million USD | 31.49% |
| 2015 Q2 | -97.11 Million USD | -111.52% |
| 2015 FY | -66.53 Million USD | -279.23% |
| 2015 Q4 | -58.64 Million USD | 11.86% |
| 2015 Q1 | -45.91 Million USD | -50.45% |
| 2014 Q1 | -27.51 Million USD | -74.88% |
| 2014 Q3 | -17.54 Million USD | 20.56% |
| 2014 Q2 | -22.08 Million USD | 19.72% |
| 2014 Q4 | -30.51 Million USD | -73.93% |
| 2014 FY | -17.54 Million USD | 13.69% |
| 2013 FY | -20.32 Million USD | -4360.85% |
| 2013 Q1 | 2.32 Million USD | -30.23% |
| 2013 Q2 | 3.57 Million USD | 53.48% |
| 2013 Q3 | -20.32 Million USD | -669.32% |
| 2013 Q4 | -15.73 Million USD | 22.61% |
| 2012 Q1 | 4.73 Million USD | 22.57% |
| 2012 Q2 | 390.27 Thousand USD | -91.76% |
| 2012 Q3 | 477.04 Thousand USD | 22.23% |
| 2012 Q4 | 3.33 Million USD | 598.92% |
| 2012 FY | 477.04 Thousand USD | 505.42% |
| 2011 FY | -117.66 Thousand USD | -108.85% |
| 2011 Q4 | 3.86 Million USD | 3385.76% |
| 2011 Q1 | 3.73 Million USD | 69.61% |
| 2011 Q3 | -117.66 Thousand USD | 72.61% |
| 2011 Q2 | -429.57 Thousand USD | -111.5% |
| 2010 Q2 | 1.46 Million USD | -69.44% |
| 2010 FY | 1.33 Million USD | -47.64% |
| 2010 Q4 | 2.2 Million USD | 65.6% |
| 2010 Q3 | 1.33 Million USD | -9.09% |
| 2010 Q1 | 4.78 Million USD | 78.11% |
| 2009 Q2 | 1.84 Million USD | 81.7% |
| 2009 Q1 | 1.01 Million USD | 207.97% |
| 2009 Q4 | 2.68 Million USD | 5.81% |
| 2009 Q3 | 2.54 Million USD | 37.94% |
| 2009 FY | 2.54 Million USD | 399.64% |
| 2008 FY | 508.39 Thousand USD | 112.9% |
| 2008 Q2 | -187.07 Thousand USD | 84.61% |
| 2008 Q4 | 329.08 Thousand USD | -35.27% |
| 2008 Q3 | 508.39 Thousand USD | 371.75% |
| 2008 Q1 | -1.21 Million USD | 55.7% |
| 2007 Q4 | -2.74 Million USD | 30.39% |
| 2007 Q1 | 3.85 Million USD | 57.3% |
| 2007 Q2 | 3.65 Million USD | -5.29% |
| 2007 Q3 | -3.94 Million USD | -207.88% |
| 2007 FY | -3.94 Million USD | -242.77% |
| 2006 Q4 | 2.45 Million USD | -11.17% |
| 2006 Q3 | 2.76 Million USD | 578.65% |
| 2006 Q1 | -932.84 Thousand USD | 28.47% |
| 2006 Q2 | -576.85 Thousand USD | 38.16% |
| 2006 FY | 2.76 Million USD | 275.35% |
| 2005 Q2 | -2.02 Million USD | 6.95% |
| 2005 Q4 | -1.3 Million USD | 17.18% |
| 2005 FY | -1.57 Million USD | -259.67% |
| 2005 Q3 | -1.57 Million USD | 22.27% |
| 2005 Q1 | -2.17 Million USD | 20.23% |
| 2004 FY | 986.14 Thousand USD | 0.0% |
| 2004 Q4 | -2.72 Million USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 262237.405% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 39.204% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 91.975% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 1475.691% |
| Rebus Holdings, Inc. | 305 Thousand USD | -1025.902% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 154.469% |
| Qrons Inc. | 351.42 Thousand USD | -877.159% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -451.767% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 92.094% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 16926.735% |
| Skye Bioscience, Inc. | -5.72 Million USD | 160.02% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 78.215% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 16.61% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -754.55% |
| SQZ Biotechnologies Company | -36.23 Million USD | 109.476% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -53.151% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -270.368% |
| Mesoblast Limited | 55.85 Million USD | 93.852% |
| Marizyme, Inc. | 18.56 Million USD | 81.507% |
| Genus plc | 190.6 Million USD | 98.198% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -53.589% |
| Pharming Group N.V. | 109.8 Million USD | 96.873% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -299.19% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -182.893% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -405.0% |
| ContraFect Corporation | -6.02 Million USD | 156.986% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -2450.524% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -197.206% |
| IMV Inc. | 7.67 Million USD | 55.231% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 37.585% |
| MultiCell Technologies, Inc. | 90.04 USD | -3813760.506% |
| ONE Bio Corp. | 9.04 Million USD | 62.013% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 567.861% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 73.474% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -151.029% |
| Q BioMed Inc. | 4.06 Million USD | 15.419% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 88.761% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -240.771% |
| Biomind Labs Inc. | 711.4 Thousand USD | -382.709% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 94.328% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -71.752% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 73.186% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -854.658% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -2356.296% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -17184.945% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -55.95% |
| GB Sciences, Inc. | 1.74 Million USD | -96.53% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1968.457% |
| HST Global, Inc. | 96.79 Thousand USD | -3447.777% |
| CSL Limited | 10.52 Billion USD | 99.967% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -1565.236% |
| Halberd Corporation | 144.72 Thousand USD | -2272.842% |
| Enzolytics Inc. | 981.65 Thousand USD | -249.817% |
| Agentix Corp. | 37.63 Thousand USD | -9025.455% |
| Resverlogix Corp. | 6.45 Million USD | 46.768% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 610.185% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.169% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 107.305% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 51.435% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -26.781% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 138.847% |
| AVAX Technologies, Inc. | -5.9 Million USD | 158.172% |
| Zenith Capital Corp. | 10.06 Thousand USD | -34021.622% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.324% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -1613.299% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -43.921% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -1987.424% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 18846.588% |
| Kadimastem Ltd | -253.1 Thousand USD | 1456.765% |
| Helix BioMedix, Inc. | -2.57 Million USD | 233.617% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 83.064% |
| BioStem Technologies, Inc. | 4.47 Million USD | 23.211% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -1606.301% |
| LadRx Corporation | -2.03 Million USD | 268.625% |
| Cell Source, Inc. | 9.23 Million USD | 62.803% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -440.645% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -440.645% |
| NovAccess Global Inc. | 2.17 Million USD | -57.634% |
| Affymax, Inc. | -5.59 Million USD | 161.354% |
| Itoco Inc. | 228.3 Thousand USD | -1404.128% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -2425.204% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 30.724% |
| Mobile Lads Corp. | 484.23 Thousand USD | -609.164% |
| CytoDyn Inc. | 20.26 Million USD | 83.052% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 530857.342% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 37150.863% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 55.437% |
| SYBLEU INC | 473.71 Thousand USD | -624.91% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 22.953% |
| International Stem Cell Corporation | 2.59 Million USD | -32.587% |
| Bioxytran, Inc. | 1.89 Million USD | -80.84% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -5402.059% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -57.458% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 59.85% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -344.469% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 374.72% |
| Neutra Corp. | 52.18 Thousand USD | -6480.183% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 237.967% |
| PureTech Health plc | -167.19 Million USD | 102.054% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1502.159% |
| IXICO plc | -4.44 Million USD | 177.263% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 74.022% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 93.739% |
| CSL Limited | 10.52 Billion USD | 99.967% |
| Cellectis S.A. | -43.81 Million USD | 107.837% |